Talos Energy Announces Public Offering Of Common Stock

PR Newswire

HOUSTON, Dec. 8, 2020 /PRNewswire/ — Talos Energy Inc. (NYSE: TALO) (the “Company”) announced today that it has commenced an underwritten public offering of 8,250,000 shares of common stock of the Company (the “Offering”). Additionally, the Company has granted the underwriter an option to purchase up to an additional 1,237,500 shares of common stock. The Company expects to use the net proceeds from the Offering to facilitate its general financing strategy and to repay a portion of its outstanding borrowings under its reserves-based lending facility as well as for general corporate purposes.

BMO Capital Markets Corp. is acting as sole underwriter for the Offering. The shares may be offered by the underwriter from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

The Offering is being made under a shelf registration statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 4, 2019. The Offering will be made only by means of a prospectus supplement and an accompanying prospectus. Before investing, prospective investors should read the prospectus supplement, the accompanying prospectus and the documents incorporated by reference therein for more complete information about the Company and the Offering. These documents may be obtained for free by visiting the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus supplement and accompanying prospectus, when available, may be obtained from BMO Capital Markets Corp., Attention: Equity Syndicate Department BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, telephone: (800)-414-3627, or by emailing [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

ABOUT TALOS ENERGY

Talos Energy (NYSE: TALO) is a technically driven independent exploration and production company focused on safely and efficiently maximizing cash flows and long-term value through its operations, currently in the United StatesGulf of Mexico and offshore Mexico. As one of the U.S. Gulf of Mexico’s largest public independent producers, we leverage decades of geology, geophysics and offshore operations expertise towards the acquisition, exploration, exploitation and development of assets in key geological trends that are present in many offshore basins around the world. Our activities in offshore Mexico provide high impact exploration opportunities in an oil rich emerging basin. For more information, visit

www.talosenergy.com

.

INVESTOR RELATIONS CONTACT

Sergio Maiworm

+1.713.328.3008
[email protected] 

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This communication contains “forward-looking statements” within the meaning of U.S. Private Securities Litigation Reform Act of 1995. When used in this communication, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “forecast”, “may,” “objective,” “plan” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All statements, other than statements of historical fact included in this communication, are forward-looking statements including, but not limited to, statements regarding the Company’s plans to issue the common stock and use the proceeds therefrom. These forward-looking statements are based on our current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events.

We caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond our control. These risks include, but are not limited to, risks and uncertainties related to economic, market or business conditions, satisfaction of customary closing conditions related to the Offering and other risk factors as detailed from time to time in the Company’s reports filed with the SEC.

Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. All forward-looking statements, expressed or implied, included in this communication are expressly qualified in their entirety by this cautionary statement. All forward-looking statements speak only as of the date of this communication. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this communication.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/talos-energy-announces-public-offering-of-common-stock-301188808.html

SOURCE Talos Energy

Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments

PR Newswire

GERMANTOWN, Md., Dec. 8, 2020 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Tuesday, December 15, 2020 at 11:00 AM ET to provide an update on the latest progress for its clinical pipeline.

The event will showcase data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBioticsTM. Precigen executives and key opinion leaders will participate in the event, including:

  • Helen Sabzevari, PhD, President and CEO of Precigen
  • Pieter Rottiers, PhD, CEO of Precigen ActoBio
  • Mary L. (Nora) Disis, MD, faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and one of the lead investigators for the PRGN-3005 clinical study
  • Kevan Herold, MD, Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine and one of the lead investigators for the AG019 clinical study

Participants may register and access the live webcast through Precigen’s investor relations website in the Press & Events section. An archived recording will be posted to the investor relations website following the event.

Precigen: Advancing Medicine with Precision
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

Trademarks
Precigen, Advancing Medicine with Precision, UltraCAR-T, and ActoBiotics are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company’s business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company’s portfolio of therapies, and in particular its CAR-T therapies, and the Company’s refocus to a healthcare-oriented business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company’s clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

For more information, contact:


Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (301) 556-9850


[email protected]  


Media Contact:

Glenn Silver

Lazar-FINN Partners


[email protected] 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-to-host-rd-update-virtual-event-on-december-15th-to-share-latest-clinical-developments-301188801.html

SOURCE Precigen, Inc.

Trecora Resources To Participate in 13th Annual LD Micro Main Event

PR Newswire

SUGAR LAND, Texas, Dec. 8, 2020 /PRNewswire/ — Trecora Resources (NYSE: TREC), a leading provider of specialty hydrocarbons and specialty waxes, today announced its upcoming conference schedule: 

  • 13th Annual LD Micro Main Event
    Date and Time: Tuesday, December 15, 2020 from 3:00 p.m. – 3:20 p.m. ET (12:00 p.m. – 12:20 p.m. PT)

There will be a live webcast for the 13th Annual LD Micro Main Event. To listen to the webcast please click the following link: https://ve.mysequire.com/

About Trecora Resources (TREC)
TREC owns and operates a specialty petrochemicals facility specializing in high purity hydrocarbons and other petrochemical manufacturing and a specialty wax facility, both located in Texas, and provides custom processing services at both facilities.

Investor Relations Contact: 
Jason Finkelstein 
The Piacente Group, Inc. 
212-481-2050 
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/trecora-resources-to-participate-in-13th-annual-ld-micro-main-event-301188598.html

SOURCE Trecora Resources

Joby Aviation Welcomes New $75M Investment From Uber As It Acquires Uber Elevate And Expands Partnership

PR Newswire

SANTA CRUZ, Calif. and SAN FRANCISCO, Dec. 8, 2020 /PRNewswire/ — Joby Aviation, a transportation company developing an all-electric, vertical take-off and landing passenger aircraft, which it intends to operate as early as 2023, today announced that Uber Technologies, Inc (NYSE: UBER) has agreed to invest a further $75 million in Joby as part of a broader transaction involving the acquisition of Uber Elevate by Joby and an expanded partnership between the two parent companies. This investment comes in addition to a previously undisclosed $50 million investment made as part of Joby’s Series C financing round in January 2020.

Under the terms of this week’s deal, Joby Aviation will acquire Uber Elevate, while the two parent companies have agreed to integrate their respective services into each other’s apps, enabling seamless integration between ground and air travel for future customers.

Established in 2016, Uber Elevate has played an important role in laying the groundwork for the aerial ridesharing market by bringing together regulators, civic leaders, real estate developers and technology companies around a shared vision for the future of air travel. Their software tools enabling market selection, demand simulation and multi-modal operations are at the center of their work, and form the basis of this future-focused deal.

JoeBen Bevirt, founder and CEO, Joby Aviation:

“We were proud to partner with Uber Elevate last year and we’re even prouder to be welcoming them into the Joby team today, while deepening our cooperation with Uber.

“The team at Uber Elevate has not only played an important role in our industry, they have also developed a remarkable set of software tools that build on more than a decade of experience enabling on-demand mobility.

“These tools and new team members will be invaluable to us as we accelerate our plans for commercial launch.”

Joby will operate an affordable, quiet and clean transportation service, using the revolutionary all-electric, vertical take-off and landing aircraft it has spent the last decade developing. With a range of up to 150 miles and a top speed of 200 mph, the vehicle and the service has the potential to make a significant difference to the lives of travelers.

Dara Khosrowshahi, CEO, Uber:

“Advanced air mobility has the potential to be exponentially positive for the environment and future generations.

“This deal allows us to deepen our partnership with Joby, the clear leader in this field, to accelerate the path to market for these technologies.

“We’re excited for their transformational mobility solution to become available to the millions of customers who rely on our platform.”

The financial terms of the acquisition were not disclosed. The transaction is expected to close in early Q1 2021, subject to regulatory review and customary closing conditions.

Uber’s new $75M investment brings its all-time total investment in Joby to $125 million and Joby Aviation’s total funding, including previous rounds, to $820 million.

About Joby Aviation

Joby Aviation is a California headquartered aerospace company developing an all-electric vertical takeoff and landing aircraft which it intends to operate as a fast, quiet and affordable air taxi service as early as 2023. The zero emissions aircraft will transport four passengers and a pilot up to 150 miles on a single charge, helping to reduce urban congestion and accelerate the shift to sustainable modes of transit. Founded in 2009, Joby has raised $820 million in investment and employs more than 500 people. Joby has offices in Santa Cruz, San Carlos and Marina, California, as well as Washington D.C. and Munich, Germany.

About Uber

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 15 billion trips later, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

Forward-Looking Statements

This communication contains forward-looking statements regarding Uber Technologies, Inc.’s (“Uber”) future business expectations which involve risks and uncertainties. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promises,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Uber’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among other things: the pending transactions between Uber and Joby Aviation, including the failure to satisfy any of the closing conditions to the proposed transaction on a timely basis or at all; and the future integration of Uber’s and Joby Aviation’s apps and expected benefits. For additional information on other potential risks and uncertainties that could cause actual results to differ from the results predicted, please see Uber’s Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Form 10-Qs or Form 8-Ks filed with the Securities and Exchange Commission. All information provided in this communication is as of the date of this communication and any forward-looking statements contained herein are based on assumptions that Uber believes to be reasonable, and information available to it, as of such date. Uber undertakes no duty to update this information unless required by law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/joby-aviation-welcomes-new-75m-investment-from-uber-as-it-acquires-uber-elevate-and-expands-partnership-301188822.html

SOURCE Joby Aviation

PDL Announces Timeline for Voluntarily Delisting from Nasdaq

Expects to File a Certificate of Dissolution on January 4, 2021

Trading in PDL’s Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020

PR Newswire

INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ — PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company’s common stock from the Nasdaq Global Select Market (“Nasdaq”).  PDL expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) and Nasdaq relating to the voluntary delisting of its common stock on or about December 28, 2020 and to suspend trading of its common stock on the Nasdaq Global Select Market prior to the opening of trading on December 31, 2020.  PDL does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq.  PDL intends to file a certificate of dissolution with the Delaware Secretary of State on or about January 4, 2021 and close its stock transfer books at the close of business on this date.  The official delisting of PDL’s common stock will be effective on or about January 7, 2021 – 10 days after the filing of the Form 25.

PDL also intends to file a Form 15 with the SEC as soon as practicable following the effectiveness of the delisting to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.  The suspension of PDL’s reporting obligations, including the obligation to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, will be effective upon filing the Form 15.  PDL does however intend to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 in March 2021.  

The voluntary delisting and deregistration are part of PDL’s previously announced voluntary Plan of Dissolution that was approved by the Board of Directors in February 2020 and at the Annual Meeting of the Company’s stockholders on August 19, 2020.  The Company’s Board of Directors considered a number of factors in determining to delist and deregister PDL’s common stock, including the costs and expenses associated with being a publicly traded company, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on Company management to comply with the continued listing and reporting requirements, all in light of the Company’s planned dissolution and liquidation.

About PDL Biopharma, Inc.
Throughout its history, PDL’s mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.  PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases.  In 2006, the Company changed its name to PDL BioPharma, Inc.

On August 19, 2020, PDL announced at the Company’s 2020 Annual Meeting of Stockholders approval by stockholders for a Plan of Dissolution authorizing the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution.  At its November 5, 2020 meeting, the Board resolved that the Certificate of Dissolution will be filed on January 4, 2021.

For more information please visit https://www.pdl.com/

NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s Plan of Dissolution, dissolution, wind-down of operations and the delisting and deregistration of the Company’s common stock.  Each of these forward-looking statements involves risks and uncertainties.  Actual results may differ materially from those, express or implied, in these forward-looking statements.  Important factors that could impair the value of the Company’s assets and business, including the implementation or success of the Company’s monetization strategy/Plan of Dissolution, are disclosed in the risk factors contained in the Company’s Annual Report on Form 10-K, filed with the SEC on March 11, 2020, in the Company’s Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2020, August 10, 2020 and November 13, 2020 and in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on July 7, 2020.  All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-announces-timeline-for-voluntarily-delisting-from-nasdaq-301188723.html

SOURCE PDL BioPharma, Inc.

Brixmor Property Group Announces Fourth Quarter 2020 Earnings Release And Teleconference Dates

PR Newswire

NEW YORK, Dec. 8, 2020 /PRNewswire/ — Brixmor Property Group Inc. (NYSE: BRX) today announced that it will release its 2020 fourth quarter earnings on Thursday, February 11, 2021 after the market close.  Brixmor will host a teleconference on Friday, February 12, 2021 at 10:00 AM ET.

Event: Brixmor Property Group’s Fourth Quarter Earnings Results

When: 10:00 AM ET, Friday, February 12, 2021

Live Webcast: Brixmor 4Q 2020 Earnings Call under the Investors tab at www.brixmor.com 

Dial #: 1.877.705.6003 (International: 1.201.493.6725)

A replay of the webcast will be available on the Brixmor website at www.brixmor.com.  A replay of the call can be accessed until midnight ET on Friday, February 26, 2021 by dialing 844.512.2921 (International: 412.317.6671); Passcode: 13713549.

Connect With Brixmor

About Brixmor Property Group
Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers. Its 395 retail centers comprise approximately 69 million square feet of prime retail space in established trade areas.  The Company strives to own and operate shopping centers that reflect Brixmor’s vision “to be the center of the communities we serve” and are home to a diverse mix of thriving national, regional and local retailers.  Brixmor is a proud real estate partner to approximately 5,000 retailers including The TJX Companies, The Kroger Co., Publix Super Markets, Wal-Mart, Ross Stores and L.A. Fitness.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/brixmor-property-group-announces-fourth-quarter-2020-earnings-release-and-teleconference-dates-301188618.html

SOURCE Brixmor Property Group Inc.

MongoDB, Inc. Announces Third Quarter Fiscal 2021 Financial Results

Third Quarter Fiscal 2021 Total Revenue of $150.8 million, up 38% Year-over-Year

Continued Strong Growth with Over 22,600 Customers as of October 31, 2020

MongoDB Atlas Revenue 47% of Total Q3 Revenue, up 61% Year-over-Year

PR Newswire

NEW YORK, Dec. 8, 2020 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB), the leading, modern general purpose database platform, today announced its financial results for the third quarter ended October 31, 2020.

“MongoDB continued to perform at a high level in the third quarter, highlighted by revenue growth that was well ahead of our expectations. The strength of our product platform and go-to-market execution has established MongoDB as a key strategic partner for any organization looking to innovate quickly to seize new opportunities or to respond to new threats,” said Dev Ittycheria, President and Chief Executive Officer of MongoDB.

“COVID-19 has further elevated the importance enterprises are placing on moving quickly to the cloud. With the recent announcement of multi-cloud clusters, MongoDB Atlas is the first cloud database to enable an application to run simultaneously across multiple cloud providers. By using MongoDB, customers not only get an easy migration path to the cloud but also the ability to leverage the best capabilities of the major cloud providers and enable true platform independence.”

Third Quarter Fiscal 2021 Financial Highlights

  • Revenue: Total revenue was $150.8 million in the third quarter fiscal 2021, an increase of 38% year-over-year. Subscription revenue was $144.1 million, an increase of 39% year-over-year, and services revenue was $6.7 million, an increase of 19% year-over-year.
  • Gross Profit: Gross profit was $104.7 million in the third quarter fiscal 2021, representing a 69% gross margin, compared to 71% in the year-ago period. Non-GAAP gross profit was $108.6 million, representing a 72% non-GAAP gross margin.
  • Loss from Operations: Loss from operations was $58.1 million in the third quarter fiscal 2021, compared to $38.7 million in the year-ago period. Non-GAAP loss from operations was $16.0 million, compared to $14.3 million in the year-ago period.
  • Net Loss: Net loss was $72.7 million, or $1.22 per share, based on 59.4 million weighted-average shares outstanding in the third quarter fiscal 2021. This compares to $42.4 million, or $0.75 per share, based on 56.4 million weighted-average shares outstanding, in the year-ago period. Non-GAAP net loss was $18.2 million or $0.31 per share. This compares to $14.6 million, or $0.26 per share, in the year-ago period.
  • Cash Flow: As of October 31, 2020, MongoDB had $966.8 million in cash, cash equivalents, short-term investments and restricted cash. During the three months ended October 31, 2020, MongoDB used $8.1 million of cash from operations, $5.6 million in capital expenditures and $1.2 million in principal repayments of finance leases, leading to negative free cash flow of $14.9 million, compared to negative free cash flow of $13.1 million in the year-ago period.

A reconciliation of each Non-GAAP measure to the most directly comparable GAAP measure has been provided in the financial statement tables included at the end of this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Third Quarter Fiscal 2021 and Recent Business Highlights

  • MongoDB Atlas became the first and only cloud database to enable customers to run an application simultaneously across multiple cloud providers. With Atlas multi-cloud clusters, organizations can now deploy a fully managed, distributed database across Amazon Web Services, Google Cloud, and Microsoft Azure simultaneously without the added operational complexity of managing data replication and migration across clouds.
  • As part of the Department of Defense’s (DoD) Enterprise DevSecOps Initiative, MongoDB was approved and released on the Iron Bank, the DoD Enterprise Artifacts Repository that hosts hardened containers. Development teams across the DoD can now utilize MongoDB to create modern applications quickly and easily within a Kubernetes environment.
  • MongoDB welcomed Tata Consultancy Services, Infosys, and Wipro to our Modernization Toolkit program to help customers modernize workloads as they migrate to the cloud. This new program provides best practices for migrating legacy data (RDBMS) to MongoDB with substantial ROI at scale.

Business Outlook

Based on information as of today, December 8, 2020, MongoDB is issuing the following financial guidance for the fourth quarter and full year fiscal 2021.


Fourth Quarter Fiscal 2021


Full Year Fiscal 2021


Revenue

$155.0 million to $157.0 million

$574.4 million to $576.4 million


Non-GAAP Loss from
O



perations

$(23.0) million to $(21.0) million

$(56.6) million to $(54.6) million


Non-GAAP Net Loss per
Share

$(0.42) to $(0.39)

$(1.07) to $(1.04)

The guidance provided above is forward-looking in nature. Actual results may differ materially. See the cautionary note regarding “Forward-Looking Statements” below. Fluctuations in MongoDB’s operating results may be particularly pronounced in the current economic environment due to the uncertainty caused by, and the unprecedented nature of, the ongoing COVID-19 pandemic, the severity, duration, and ultimate impact of which is difficult to predict at this time. The situation regarding COVID-19 remains uncertain and could change rapidly, and MongoDB will continue to evaluate its potential impact on its business.

Reconciliation of non-GAAP loss from operations and non-GAAP net loss per share guidance to the most directly comparable GAAP measures is not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and low visibility with respect to the charges excluded from these non-GAAP measures; in particular, the measures and effects of stock-based compensation expense specific to equity compensation awards that are directly impacted by unpredictable fluctuations in our stock price. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results.

Conference Call Information

MongoDB will host a conference call today, December 8, 2020, at 5:00 p.m. (Eastern Time) to discuss its financial results and business outlook. A live webcast of the call will be available on the “Investor Relations” page of MongoDB’s website at https://investors.mongodb.com. To access the call by phone, dial 844-808-6880 (domestic) or 1-412-317-5284 (international). A replay of this conference call will be available for a limited time at 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID is 10150178. A replay of the webcast will also be available for a limited time at https://investors.mongodb.com.

About MongoDB

MongoDB is the leading modern, general purpose database platform, designed to unleash the power of software and data for developers and the applications they build. Headquartered in New York, MongoDB has more than 22,600 customers in over 100 countries. The MongoDB database platform has been downloaded over 130 million times and there have been more than one million MongoDB University registrations.

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning our financial guidance for the fourth fiscal quarter and full year fiscal 2021; the anticipated impact of the COVID-19 pandemic on our business and future operating results; and the potential benefits of our product platform. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would” or the negative or plural of these words or similar expressions or variations. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control including, without limitation: the impact that the precautions we have taken in our business relative to the ongoing COVID-19 pandemic may have on our business; the financial impacts of the COVID-19 pandemic on our customers, our potential customers, the global financial markets and our business and future operating results; our potential failure to meet publicly announced guidance or other expectations about our business and future operating results; our limited operating history; our history of losses; failure of our database platform to satisfy customer demands; the effects of increased competition; our investments in new products and our ability to introduce new features, services or enhancements; our ability to effectively expand our sales and marketing organization; our ability to continue to build and maintain credibility with the developer community; our ability to add new customers or increase sales to our existing customers; our ability to maintain, protect, enforce and enhance our intellectual property; the growth and expansion of the market for database products and our ability to penetrate that market; our ability to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions; our ability to maintain the security of our software and adequately address privacy concerns; our ability to manage our growth effectively and successfully recruit and retain additional highly-qualified personnel; and the price volatility of our common stock. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended July 31, 2020 filed with the SEC on September 3, 2020. Additional information will be made available in our Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2020 and other filings and reports that we may file from time to time with the SEC. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

Non-GAAP Financial Measures

This press release includes the following financial measures defined as non-GAAP financial measures by the SEC: non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share and free cash flow. Non-GAAP gross profit and non-GAAP gross margin exclude stock-based compensation expense. Non-GAAP operating expenses, non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share exclude:

  • stock-based compensation expense;
  • amortization of intangible assets for the acquired technology and acquired customer relationships associated with the prior acquisitions of Realm, mLab and WiredTiger;
  • amortization of time-based founder payments associated with the mLab purchase that was deemed to be compensation expense for GAAP purposes;
  • acquisition costs associated with the purchase of Realm in fiscal 2020; and
  • in the case of non-GAAP net loss, non-cash interest expense related to our convertible senior notes and a non-recurring income tax benefit associated with the acquisition of Realm intangible assets in fiscal 2020.

MongoDB uses these non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to GAAP measures, in evaluating MongoDB’s ongoing operational performance. MongoDB believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing its financial results with other companies in MongoDB’s industry, many of which present similar non-GAAP financial measures to investors.

Free cash flow represents net cash used in operating activities less capital expenditures, principal repayments of finance lease liabilities and capitalized software development costs, if any. MongoDB uses free cash flow to understand and evaluate its liquidity and to generate future operating plans. The exclusion of capital expenditures, principal repayments of finance lease liabilities and amounts capitalized for software development facilitates comparisons of MongoDB’s liquidity on a period-to-period basis and excludes items that it does not consider to be indicative of its liquidity. MongoDB believes that free cash flow is a measure of liquidity that provides useful information to investors in understanding and evaluating the strength of its liquidity and future ability to generate cash that can be used for strategic opportunities or investing in its business in the same manner as MongoDB’s management and board of directors.

Non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. In particular, other companies may report non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, free cash flow or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures, as presented below. This earnings press release and any future releases containing such non-GAAP reconciliations can also be found on the Investor Relations page of MongoDB’s website at https://investors.mongodb.com.

Investor Relations

Brian Denyeau

ICR for MongoDB
646-277-1251
[email protected]

Media Relations

Ben Wolfson/Tom McMahon
MongoDB
[email protected]

 


MONGODB, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(unaudited)


October 31,
2020


January 31,
2020


Assets

Current assets:

Cash and cash equivalents  

$

414,762

$

706,192

Short-term investments  

551,539

280,326

Accounts receivable, net of allowance for doubtful accounts of $4,710 and $2,515 as of October 31,
2020 and January 31, 2020, respectively 

91,784

85,554

Deferred commissions  

30,090

24,219

Prepaid expenses and other current assets  

15,611

16,905

Total current assets  

1,103,786

1,113,196

Property and equipment, net  

63,588

58,316

Operating lease right-of-use assets

36,909

11,147

Goodwill  

55,830

55,830

Acquired intangible assets, net

28,400

34,779

Deferred tax assets  

728

615

Other assets  

66,620

54,684

Total assets  

$

1,355,861

$

1,328,567


Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable  

$

3,644

$

2,849

Accrued compensation and benefits  

56,802

41,427

Operating lease liabilities

4,314

3,750

Other accrued liabilities  

27,457

26,860

Deferred revenue  

179,322

167,498

Total current liabilities  

271,539

242,384

Deferred tax liability, non-current  

828

821

Operating lease liabilities, non-current

36,501

8,113

Deferred revenue, non-current  

16,497

23,281

Convertible senior notes, net

947,652

911,075

Other liabilities, non-current

61,040

60,035

Total liabilities  

1,334,057

1,245,709

Stockholders’ equity:

Class A common stock, par value of $0.001 per share; 1,000,000,000 shares authorized as of October
31, 2020 and January 31, 2020; 60,255,524 shares issued and 60,156,153 shares outstanding as of
October 31, 2020; 48,512,090 shares issued and outstanding as of January 31, 2020

60

48

Class B common stock, par value of $0.001 per share; no shares and 100,000,000 authorized as of
October 31, 2020 and January 31, 2020, respectively; no shares issued and outstanding as of October
31, 2020; 8,969,824 shares issued and 8,870,453 shares outstanding as of January 31, 2020

9

Additional paid-in capital  

883,002

752,127

Treasury stock, 99,371 shares (repurchased at an average of $13.27 per share) as of October 31,
2020 and January 31, 2020

(1,319)

(1,319)

Accumulated other comprehensive income (loss)

(337)

225

Accumulated deficit  

(859,602)

(668,232)

Total stockholders’ equity

21,804

82,858

Total liabilities and stockholders’ equity

$

1,355,861

$

1,328,567

 


MONGODB, INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)


Three Months Ended October 31,


Nine Months Ended October 31,


2020


2019


2020


2019

Revenue:

Subscription

$

144,069

$

103,827

$

401,403

$

281,977

Services

6,702

5,614

17,978

16,220

Total revenue

150,771

109,441

419,381

298,197

Cost of revenue(1):

Subscription

38,642

26,497

103,240

73,465

Services

7,468

5,694

22,851

17,100

Total cost of revenue

46,110

32,191

126,091

90,565

Gross profit

104,661

77,250

293,290

207,632

Operating expenses:

Sales and marketing(1)

83,214

57,015

227,417

156,659

Research and development(1)

54,363

39,387

149,250

107,395

General and administrative(1)

25,175

19,562

66,534

50,541

Total operating expenses

162,752

115,964

443,201

314,595

Loss from operations

(58,091)

(38,714)

(149,911)

(106,963)

Other loss, net

(13,634)

(3,110)

(39,090)

(8,916)

Loss before provision for income taxes

(71,725)

(41,824)

(189,001)

(115,879)

Provision for (benefit from) income taxes

926

559

2,142

(2,920)

Net loss

$

(72,651)

$

(42,383)

$

(191,143)

$

(112,959)

Net loss per share, basic and diluted

$

(1.22)

$

(0.75)

$

(3.27)

$

(2.03)

Weighted-average shares used to compute net loss per share, basic and diluted

59,368,167

56,411,779

58,476,521

55,600,484

________________________


(1)     

    Includes stock–based compensation expense as follows:


Three Months Ended October 31,


Nine Months Ended October 31,


2020


2019


2020


2019

Cost of revenue—subscription

$

2,446

$

1,274

$

6,508

$

3,476

Cost of revenue—services

1,513

793

4,142

2,107

Sales and marketing

14,696

6,844

38,754

17,728

Research and development

15,442

6,879

41,415

17,513

General and administrative

5,855

3,577

17,225

10,214

Total stock–based compensation expense

$

39,952

$

19,367

$

108,044

$

51,038

 


MONGODB, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


Three Months Ended October 31,


Nine Months Ended October 31,


2020


2019


2020


2019


Cash flows from operating activities

Net loss  

$

(72,651)

$

(42,383)

$

(191,143)

$

(112,959)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization  

3,793

3,793

9,515

9,824

Stock-based compensation  

39,952

19,367

108,044

51,038

Amortization of debt discount and issuance costs

12,360

3,335

36,577

9,833

Amortization of finance right-of-use assets

993

994

2,981

2,982

Amortization of operating right-of-use assets

1,893

936

4,747

2,055

Non-cash interest on finance lease liabilities

1,823

Deferred income taxes  

60

(309)

(88)

(4,541)

Accretion of discount on short-term investments

604

(868)

383

(3,619)

Unrealized foreign exchange (gain) loss

(1,915)

(1,915)

Change in operating assets and liabilities:

Accounts receivable  

(1,749)

(1,097)

(4,157)

5,123

Prepaid expenses and other current assets  

(1,599)

314

247

189

Deferred commissions  

(8,168)

(5,159)

(17,161)

(12,205)

Other long-term assets  

39

(175)

(117)

(148)

Accounts payable  

2,153

(592)

743

(152)

Accrued liabilities  

16,240

7,891

19,633

16,176

Operating lease liabilities

(2,699)

(895)

(2,737)

(1,979)

Deferred revenue  

809

2,565

5,765

14,898

Other liabilities, non-current

1,765

740

4,655

740

Net cash used in operating activities  

(8,120)

(11,543)

(24,028)

(20,922)


Cash flows from investing activities

Purchases of property and equipment  

(5,646)

(754)

(10,942)

(2,350)

Acquisition, net of cash acquired

(38,629)

Investment in non-marketable securities

(500)

(500)

Proceeds from maturities of marketable securities  

255,000

130,000

540,000

410,000

Purchases of marketable securities  

(302,568)

(154,505)

(812,574)

(363,530)

Net cash provided by (used in) investing activities   

(53,714)

(25,259)

(284,016)

5,491


Cash flows from financing activities

Payments of issuance costs for convertible senior notes

(4,154)

Proceeds from exercise of stock options, including early exercised 
     stock options  

6,747

1,933

13,798

13,283

Proceeds from the issuance of common stock under the Employee 
     Stock Purchase Plan

8,963

6,394

Repurchase of early exercised stock options  

(4)

(11)

(35)

Principal repayments of finance leases

(1,166)

(798)

(3,450)

(798)

Proceeds from tenant improvement allowance on finance lease

856

856

Net cash provided by financing activities  

6,437

1,131

16,002

18,844

Effect of exchange rate changes on cash, cash equivalents, and restricted
      cash  

665

295

618

62

Net increase (decrease) in cash, cash equivalents, and restricted cash  

(54,732)

(35,376)

(291,424)

3,475

Cash, cash equivalents, and restricted cash, beginning of period  

470,014

187,198

706,706

148,347

Cash, cash equivalents, and restricted cash, end of period  

$

415,282

$

151,822

$

415,282

$

151,822

 


MONGODB, INC.

RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES

(in thousands, except share and per share data)

(unaudited)


Three Months Ended October 31,


Nine Months Ended October 31,


2020


2019


2020


2019


Reconciliation of GAAP gross profit to non-GAAP gross profit:

Gross profit on a GAAP basis

$

104,661

$

77,250

$

293,290

$

207,632


Gross margin (Gross profit/Total revenue) on a GAAP basis


69


%


71


%


70


%


70


%

Add back:

Stock-based compensation expense: Cost of Revenue—
Subscription

2,446

1,274

6,508

3,476

Stock-based compensation expense: Cost of Revenue—Services

1,513

793

4,142

2,107

Non-GAAP gross profit

$

108,620

$

79,317

$

303,940

$

213,215


Non-GAAP gross margin (Non-GAAP gross profit/Total revenue)


72


%


72


%


72


%


72


%


Reconciliation of GAAP operating expenses to non-GAAP
operating expenses:

Sales and marketing operating expense on a GAAP basis

$

83,214

$

57,015

$

227,417

$

156,659

Less:

Stock-based compensation expense

14,696

6,844

38,754

17,728

Amortization of intangible assets associated with acquisitions

760

766

2,284

2,212

Non-GAAP sales and marketing operating expense

$

67,758

$

49,405

$

186,379

$

136,719

Research and development operating expense on a GAAP basis

$

54,363

$

39,387

$

149,250

$

107,395

Less:

Stock-based compensation expense

15,442

6,879

41,415

17,513

Amortization of intangible assets and time-based founder
payments associated with acquisitions

1,365

4,261

6,001

11,413

Non-GAAP research and development operating expense

$

37,556

$

28,247

$

101,834

$

78,469

General and administrative operating expense on a GAAP basis

$

25,175

$

19,562

$

66,534

$

50,541

Less:

Stock-based compensation expense

5,855

3,577

17,225

10,214

Acquisition costs

64

641

Non-GAAP general and administrative operating expense

$

19,320

$

15,921

$

49,309

$

39,686


Reconciliation of GAAP loss from operations to non-GAAP loss
from operations:

Loss from operations on a GAAP basis

$

(58,091)

$

(38,714)

$

(149,911)

$

(106,963)

Add back:

Stock-based compensation expense

39,952

19,367

108,044

51,038

Amortization of intangible assets and time-based founder
payments associated with acquisitions

2,125

5,027

8,285

13,625

Acquisition costs

64

641

Non-GAAP loss from operations

$

(16,014)

$

(14,256)

$

(33,582)

$

(41,659)


Reconciliation of GAAP net loss to non-GAAP net loss:

Net loss on a GAAP basis

$

(72,651)

$

(42,383)

$

(191,143)

$

(112,959)

Add back:

Stock-based compensation expense

39,952

19,367

108,044

51,038

Amortization of intangible assets and Founder Holdback
associated with acquisitions

2,125

5,027

8,285

13,625

Acquisition costs

64

641

Non-cash interest expense related to convertible senior notes

12,360

3,335

36,577

9,833

Non-recurring income tax benefit associated with the acquisition
of Realm intangible assets

(3,536)

Non-GAAP net loss

$

(18,214)

$

(14,590)

$

(38,237)

$

(41,358)


Reconciliation of GAAP net loss per share, basic and diluted, to
non-GAAP net loss per share, basic and diluted:

Net loss per share, basic and diluted, on a GAAP basis

$

(1.22)

$

(0.75)

$

(3.27)

$

(2.03)

Add back:

Stock-based compensation expense

0.67

0.34

1.85

0.92

Amortization of intangible assets and Founder Holdback

associated with acquisitions

0.03

0.09

0.14

0.24

Acquisition costs

0.01

Non-cash interest expense related to convertible senior notes

0.21

0.06

0.63

0.18

Non-recurring income tax benefit associated with the acquisition
of Realm intangible assets

(0.06)

Non-GAAP net loss per share, basic and diluted

$

(0.31)

$

(0.26)

$

(0.65)

$

(0.74)

 

The following table presents a reconciliation of free cash flow to net cash used in operating activities, the most directly
comparable GAAP measure, for each of the periods indicated (unaudited, in thousands):


Three Months Ended October 31,


Nine Months Ended October 31,


2020


2019


2020


2019

Net cash used in operating activities  

$

(8,120)

$

(11,543)

$

(24,028)

$

(20,922)

Capital expenditures   

(5,646)

(754)

(10,942)

(2,350)

Principal repayments of finance lease liabilities

(1,166)

(798)

(3,450)

(798)

Capitalized software

Free cash flow  

$

(14,932)

$

(13,095)

$

(38,420)

$

(24,070)

 


MONGODB, INC.

CUSTOMER COUNT METRICS

The following table presents certain customer count information as of the periods indicated:


10/31/2018


1/31/2019


4/30/2019


7/31/2019


10/31/2019


1/31/2020


4/30/2020


7/31/2020


10/31/2020

Total Customers

8,300+

13,400+

14,200+

15,000+

15,900+

17,000+

18,400+

20,200+

22,600+

Direct Sales Customers(a)

1,700+

1,750+

1,800+

1,850+

1,900+

2,000+

2,200+

2,500+

2,800+

MongoDB Atlas Customers

6,200+

11,400+

12,300+

13,200+

14,200+

15,400+

16,800+

18,800+

21,100+

Customers over $100K(b)

490

557

598

622

688

751

780

819

898

(a) 

Direct Sales Customers are customers that were sold through our direct sales force and channel partners.

(b) 

Represents the number of customers with $100,000 or greater in annualized recurring revenue (“ARR”)
and annualized monthly recurring revenue (“MRR”). ARR includes the revenue we expect to receive from
our customers over the following 12 months based on contractual commitments and, in the case of Direct
Sales Customers of MongoDB Atlas, by annualizing the prior 90 days of their actual consumption of
MongoDB Atlas, assuming no increases or reductions in their subscriptions or usage. For all other
customers of our self-serve products, we calculate annualized MRR by annualizing the prior 30 days
of their actual consumption of such products, assuming no increases or reductions in usage. ARR and
annualized MRR exclude professional services. Prior to January 31, 2020, ARR from Direct Sales
Customers of MongoDB Atlas was based on their contractual commitments, regardless of their actual
consumption. We believe that our new consumption-based ARR calculation better reflects actual
customer behavior. The impact of this change on prior reported periods is immaterial.

 

 


MONGODB, INC.

SUPPLEMENTAL REVENUE INFORMATION

The following table presents certain supplemental revenue information as of the periods indicated:


10/31/2018


1/31/2019


4/30/2019


7/31/2019


10/31/2019


1/31/2020


4/30/2020


7/31/2020


10/31/2020

MongoDB Enterprise 
     Advanced: % of 
     Subscription Revenue

59

%

53

%

54

%

52

%

46

%

48

%

49

%

45

%

43

%

Direct Sales 
     Customers(a)

Revenue: % of 
     Subscription Revenue

87

%

77

%

77

%

78

%

78

%

79

%

79

%

81

%

82

%

(a) 

Direct Sales Customers are customers that were sold through our direct sales force and channel partners.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mongodb-inc-announces-third-quarter-fiscal-2021-financial-results-301188829.html

SOURCE MongoDB, Inc.

Prologis Declares Quarterly Dividends

PR Newswire

SAN FRANCISCO, Dec. 8, 2020 /PRNewswire/ — The Board of Directors of Prologis, Inc. (NYSE: PLD) declared a regular cash dividend for the quarter ending December 31, 2020, on the following securities:

  • A dividend of $0.58 per share of the company’s common stock, payable on December 31, 2020, to common stockholders of record at the close of business on December 18, 2020; and
  • A dividend of $1.0675 per share of the company’s 8.54% Series Q Cumulative Redeemable Preferred Stock, payable on December 31, 2020, to Series Q stockholders of record at the close of business on December 18, 2020.

ABOUT PROLOGIS

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of September 30, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 976 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

FORWARD-LOOKING STATEMENTS

The statements in this document that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which we operate as well as management’s beliefs and assumptions. Such statements involve uncertainties that could significantly impact our financial results. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” and “estimates,” including variations of such words and similar expressions, are intended to identify such forward-looking statements, which generally are not historical in nature. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to rent and occupancy growth, development activity, contribution and disposition activity, general conditions in the geographic areas where we operate, our debt, capital structure and financial position, our ability to form new co-investment ventures and the availability of capital in existing or new co-investment ventures — are forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that our expectations will be attained and, therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Some of the factors that may affect outcomes and results include, but are not limited to: (i) national, international, regional and local economic and political climates; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties; (v) maintenance of real estate investment trust status, tax structuring and changes in income tax laws and rates; (vi) availability of financing and capital, the levels of debt that we maintain and our credit ratings; (vii) risks related to our investments in our co-investment ventures, including our ability to establish new co-investment ventures; (viii) risks of doing business internationally, including currency risks; (ix) environmental uncertainties, including risks of natural disasters; (x) risks related to the current coronavirus pandemic; and (xi) those additional factors discussed in reports filed with the Securities and Exchange Commission by us under the heading “Risk Factors.” We undertake no duty to update any forward-looking statements appearing in this document except as may be required by law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/prologis-declares-quarterly-dividends-301188782.html

SOURCE Prologis, Inc.

WhiteHorse Finance, Inc. Comments on Recent Transfer of Common Shares by H.I.G. Capital, LLC Affiliates

PR Newswire

NEW YORK, Dec. 8, 2020 /PRNewswire/ — WhiteHorse Finance, Inc. (“WhiteHorse Finance” or the “Company”) (Nasdaq: WHF) today issued the following statement regarding the recent ownership transfer of common shares held by funds affiliated by H.I.G. Capital:

“On December 7, 2020, H.I.G. Bayside Debt & LBO Fund II, L.P. and H.I.G. Bayside Loan Opportunity Fund II, L.P. (the “Legacy Bayside Funds”), funds affiliated with and managed by H.I.G. Capital, agreed to sell their collective ownership interests in WhiteHorse Finance, comprised of 4,863,172 shares of the Company’s common stock, to H.I.G. Bayside Loan Opportunity Fund IV, L.P. (“Bayside Fund IV”), which is also affiliated with and managed by H.I.G. Capital.  The terms of the agreement were not disclosed.

The transaction will transfer 2,679,622 shares from H.I.G. Bayside Debt & LBO Fund II, L.P. and 2,183,550 shares from H.I.G. Bayside Loan Opportunity Fund II, L.P. to Bayside Fund IV.  It is expected that Bayside Fund IV would have the ability to own these common shares for a minimum of three years.

Since March 31, 2019, the Legacy Bayside Funds, collectively, WhiteHorse Finance’s largest shareholder, have sold over half of their position in WhiteHorse Finance to the public markets, reducing their holdings from 51.25% of shares outstanding to 23.67% as of September 30, 2020.

This reduction in the Legacy Bayside Funds’ position since 2019 was made following extensive input from WhiteHorse Finance shareholders with the goal of improving liquidity in the Company’s shareholder base. 

The announced share transfer was executed due to the Legacy Bayside Funds reaching the end of their terms; the Legacy Bayside Funds have held shares of WhiteHorse Finance since the Company’s IPO in 2012. The transfer does not preclude Bayside Fund IV from selling additional shares of WhiteHorse Finance to the public markets in the future.”

About WhiteHorse Finance, Inc.

WhiteHorse Finance, Inc. is a business development company that originates and invests in loans to privately held, lower middle market companies across a broad range of industries. The Company’s investment activities are managed by its investment adviser, H.I.G. WhiteHorse Advisers, LLC, an affiliate of H.I.G. Capital, LLC (“H.I.G. Capital”). H.I.G. Capital is a leading global alternative asset manager with approximately $42 billion of capital under management* across a number of funds focused on the small and mid-cap markets. For more information about H.I.G. Capital, please visit http://www.higcapital.com. For more information about the Company, please visit http://www.whitehorsefinance.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Contacts

Stuart Aronson

WhiteHorse Finance, Inc.
212-506-0500
[email protected] 

Joyson Thomas

WhiteHorse Finance, Inc.
305-379-2322
[email protected]

Sean Silva

Prosek Partners
646-818-9122
[email protected]  

 

Cision View original content:http://www.prnewswire.com/news-releases/whitehorse-finance-inc-comments-on-recent-transfer-of-common-shares-by-hig-capital-llc-affiliates-301188817.html

SOURCE WhiteHorse Finance, Inc.

Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors

Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors.

Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology at the University of California San Francisco. He is an international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development of multiple immunotherapies, including the first medicine approved by the U.S. Food and Drug Administration (FDA) targeting T-cell co-stimulation to treat autoimmunity and the first FDA-approved checkpoint inhibitor for the treatment of metastatic melanoma. Dr. Bluestone was the founding director of the Immune Tolerance Network, the largest National Institutes of Health-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy. He recently led the Parker Institute for Cancer Immunotherapy as President and Chief Executive Officer. He served as a member of the Blue Ribbon Panel, appointed by then Vice President Joe Biden, to guide the National Cancer Moonshot Initiative. Dr. Bluestone is a member of the National Academy of Medicine and American Academy of Arts and Sciences, was a recipient of the prestigious Guggenheim Fellowship, and previously served as the Ludwig Professor and Director of the Ben May Institute at the University of Chicago.

“We are very pleased to welcome Jeff Bluestone to our Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Jeff is an exceptional scientist and researcher who has had a distinguished career in the field of immunotherapy. His scientific acumen will be a valuable addition to the Gilead Board, as we continue to deliver transformational medicines to patients.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Douglas Maffei, PhD, Investors

(650) 522-2739

Marni Kottle, Media

(650) 522-5388

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Hospitals Health Pharmaceutical Oncology

MEDIA:

Logo
Logo